Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2019

Open Access 01-12-2019 | Prostate Cancer | Original research

Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Authors: Romain Schollhammer, Henri De Clermont Gallerande, Mokrane Yacoub, Marie-Laure Quintyn Ranty, Nicole Barthe, Delphine Vimont, Elif Hindié, Philippe Fernandez, Clément Morgat

Published in: EJNMMI Research | Issue 1/2019

Login to get access

Abstract

Purpose

Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer.

Procedures

We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks).

Results

Binding of 111In-PSMA-617 was high whatever the metastatic risk (p = 0.665), Gleason score (p = 0.555), or PSA value (p = 0.404) while 111In-RM2 exhibited a significantly higher binding in the low metastatic risk group (p = 0.046), in the low PSA value group (p = 0.001), and in samples with Gleason 6 score (p = 0.006).

Conclusion

PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRef
2.
Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.CrossRef
3.
Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.CrossRef
4.
Morgat C, Mishra AK, Varshney R, et al. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med. 2014;55:1650–7.CrossRef
5.
Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52.CrossRef
6.
Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941–9.CrossRef
7.
Mansi R, Fleischmann A, Mäcke HR, Reubi JC. Targeting GRPR in urological cancers--from basic research to clinical application. Nat Rev Urol. 2013;10:235–44.CrossRef
8.
Kahkonen E, Jambor I, Kemppainen J, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434–43.CrossRef
9.
Nock BA, Kaloudi A, Lymperis E, et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017;58:75–80.CrossRef
10.
Zhang J, Niu G, Fan X, et al. PET using a GRPR antagonist 68 Ga-RM26 in healthy volunteers and prostate cancer patients. J Nucl Med. 2018;59:922–8.CrossRef
11.
Beer M, Montani M, Gerhardt J, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318–25.CrossRef
12.
Körner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217–24.CrossRef
13.
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.CrossRef
14.
Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969–77.PubMed
15.
Mansi R, Abiraj K, Wang X, et al. Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors. J Med Chem. 2015;58:682–91.CrossRef
16.
Gourni E, Canovas C, Goncalves V, et al. (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors. PLoS One. 2015;10:e0145755.CrossRef
17.
Borkowski S, DOEHR O, HULTSCH C, et al. Preclinical validation of the Ga-68- bombesin antagonist BAY 86-7548 for a phase I study in prostate cancer patients. J Nucl Med. 2012;53(supplement 1):177.
18.
Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.CrossRef
19.
Morgat C, Schollhammer R, Macgrogan G, et al. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS One. 2019;14:e0210905.CrossRef
20.
Spick C, Herrmann K, Czernin J. Evaluation of prostate cancer with 11C-acetate PET/CT. J Nucl Med. 2016;57:30S–7S.CrossRef
21.
Parent EE, Schuster DM. Update on 18F-Fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018;59:733–9.CrossRef
22.
Nitsch S, Hakenberg OW, Heuschkel M, et al. Evaluation of prostate cancer with 11C- and 18F-choline PET/CT: diagnosis and initial staging. J Nucl Med. 2016;57:38S–42S.CrossRef
23.
Liu C, Liu T, Zhang N, et al. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2018;45:1852–61.CrossRef
24.
Touijer KA, Michaud L, Alvarez HAV, et al. Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer. Eur Urol Oncol. 2018;2(2):166–73.CrossRef
25.
Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med. 2018;59:238–43.CrossRef
26.
Moschini M, Carroll PR, Eggener SE, et al. Low-risk prostate cancer: identification, management, and outcomes. Eur Urol. 2017;72:238–49.CrossRef
27.
Porcaro AB, Siracusano S, de Luyk N, et al. Low-risk prostate cancer and tumor upgrading in the surgical specimen: analysis of clinical factors predicting tumor upgrading in a contemporary series of patients who were evaluated according to the modified Gleason score grading system. Curr Urol. 2017;10:118–25.CrossRef
28.
Storz E, Shah A, Zettinig O, et al. PSMA-PET/MRI-guided transrectal fusion biopsy for the detection of prostate cancer. Eur Urol Suppl. 2015;14:e217.CrossRef
29.
Zettinig O, Shah A, Hennersperger C, et al. Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. Int J Comput Assist Radiol Surg. 2015;10:1997–2007.CrossRef
30.
Calais J, Kishan AU, Cao M, et al. Potential impact of 68 Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. J Nucl Med. 2018;59:1714–21.CrossRef
Metadata
Title
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
Authors
Romain Schollhammer
Henri De Clermont Gallerande
Mokrane Yacoub
Marie-Laure Quintyn Ranty
Nicole Barthe
Delphine Vimont
Elif Hindié
Philippe Fernandez
Clément Morgat
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2019
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-019-0517-6

Other articles of this Issue 1/2019

EJNMMI Research 1/2019 Go to the issue

Original research

Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers

Original research

Impact of non-uniform attenuation correction in a dynamic [18F]-FDOPA brain PET/MRI study

Original research

Comparison between silicon photomultiplier-based and conventional PET/CT in patients with suspected lung cancer—a pilot study

Original research

Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models

Original research

First-in-class positron emission tomography tracer for the glucagon receptor

Original research

Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc